Skip to content
Esta página está disponible en españolCambiar →

T. Rowe Price Investment Management portfolio

Investment firm

Portfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

T. Rowe Price Investment Management reported a $152 bn portfolio of 734 companies (736 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are GOOGL, AMZN, MSFT.

Stock portfolio
$152 bn
Companies
734
736 positions (by CUSIP)Top 10: 19%
Turnover
24%
Copying its 13F, 5 years
—
Not calculated: not counted as a concentrated manager

Sections with a free account

What it reported after the quarter end (Q2 2026)

The 13F shows the portfolio as of Jun 30, 2026. Since then T. Rowe Price Investment Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.

  • 13G/AESABESAB13.2 % → 6.2 %

    Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗

  • 13G/ABANC of CaliforniaBANC9.3 % → 10.1 %

    Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗

  • 13G/ABicara TherapeuticsBCAX10.1 % → 4.2 %

    Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗

  • 13G/AUL SolutionsULS8.5 % → 10.7 %

    Stake reported in the company · event of Sep 30, 2026 · filed Oct 7, 2026 · filing ↗

  • 13G/ARevvityRVTY16.4 % → 9.2 %

    Stake reported in the company · event of Aug 31, 2026 · filed Sep 8, 2026 · filing ↗

  • 13GTeamsharesTMS18.3 %

    Stake reported in the company · event of Aug 31, 2026 · filed Sep 8, 2026 · filing ↗

  • 13G/ABioLife SolutionsBLFS13.5 % → 7.5 %

    Stake reported in the company · event of Aug 31, 2026 · filed Sep 8, 2026 · filing ↗

  • 13G/ADianthus TherapeuticsDNTH7.1 % → 12.1 %

    Stake reported in the company · event of Jul 31, 2026 · filed Aug 7, 2026 · filing ↗

Plus 53 more, in its EDGAR filings.

What changed this quarter

721 positions with a change (150 new, 224 added to, 278 trimmed, 69 sold); also, 17 entered through an IPO, 4 exited through an acquisition or merger, 1 entered through a spin-off. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).

The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.

Top holdings

Portfolio by sector

  • ● Information Technology 26%
  • ● Health Care 19%
  • ● Industrials 11%
  • ● Financials 11%
  • ● Consumer Discretionary 10%
  • ● Communication Services 7%
  • ● Utilities 6%
  • ● Energy 4%
  • ● Consumer Staples 2%
  • ● Materials 2%
  • ● Real Estate 2%

13F filings with amendments or confidential positions

Stakes above 5% (13D/13G)

Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.

How we classify it

Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided

Similar managers by type and size

Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.

Follow T. Rowe Price Investment Management for free

When the next 13F is filed, we email you (if you turn it on) and it shows in your list. No credit card.

Follow T. Rowe Price Investment Management